1 day+3.30%
1 week+58.45%
Current month+78.26%
1 month+89.59%
3 months+63.18%
6 months+35.54%
Current year+19.97%
1 week 4.03
Extreme 4.0257
7.78
1 month 3.38
Extreme 3.3801
7.78
Current year 3.1
Extreme 3.1
7.78
1 year 3.1
Extreme 3.1
7.78
3 years 3.1
Extreme 3.1
31.2
5 years 3.1
Extreme 3.1
280.6
10 years 3.1
Extreme 3.1
861.4
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 14/05/2024
Chief Executive Officer 55 14/05/2024
Chief Operating Officer 61 14/05/2024
Director TitleAgeSince
Director/Board Member 64 30/11/2020
Director/Board Member 55 14/05/2024
Chairman 56 03/09/2024
Date Insider Type Main position Quantity % Market Cap. Importance
18/09/26 Sell

Chief Operating Officer

-6,850 0.3556%
18/09/26 Sell

Controller/Auditor

-4,077 0.2116%
18/09/26 Sell

Chief Executive Officer

-9,132 0.4741%
Change 5-day change 1-year change 3-year change Capi.($)
+3.30%+58.45% - - 12.69M
+0.65%-3.56%+33.53%+60.50% 63.48B
+1.76%+1.27%+11.82%+82.12% 54.55B
-0.94%+0.99%+10.45%+102.18% 53.59B
+2.06%-0.10%+26.70%+55.99% 44.75B
+1.84%-3.36%+17.87%+100.14% 41.62B
+0.24%-3.77%+221.40%+918.86% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+47.63%+107.12%+94.27% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +4.21%-0.42%+51.65%+161.85% 42.27B
Weighted average by Cap. +2.99%-0.29%+47.09%+160.53%
Logo Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in half-life-extended multispecific antibodies designed to deliver therapies. Through the proprietary INSPIRE platform, the Company combines complementary therapeutic mechanisms in fully IgG-based molecules designed for efficacy and extended exposure. Its lead program, PRA-216, is a novel IL-4Ra/TSLP bispecific antibody in Phase II development in asthma, chronic obstructive pulmonary disease, and atopic dermatitis, with a fourth Phase II study planned in eosinophilic esophagitis. In addition to PRA-216, the Company is advancing a wholly owned pipeline of additional INSPIRE-based multispecific programs across diseases with significant unmet need. Its second program is an IL-31 containing bispecific antibody being developed initially for atopic dermatitis. The Company is open to various partnering programs, including BDC-3042: P2-ready Dectin-2 Agonist mA, Preclinical CEA ISAC and Preclinical PD-L1 ISAC.
Employees
-
Date Price Change Volume
28/10/26 US$6.560 +2.98% 55,440
27/10/26 US$6.370 -3.34% 177,798
26/10/26 US$6.590 +5.10% 423,695
23/10/26 US$6.270 +49.64% 12,882,703
22/10/26 US$4.190 +1.21% 14,054
  1. Stock Market
  2. Stocks
  3. BOLT Stock